See more : Panasonic Holdings Corporation (6752.T) Income Statement Analysis – Financial Results
Complete financial analysis of Adial Pharmaceuticals, Inc. (ADIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adial Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MARX Biotech Co., Ltd. (7731.TWO) Income Statement Analysis – Financial Results
- Ryman Healthcare Limited (RHCGF) Income Statement Analysis – Financial Results
- Gray Television, Inc. (GTN-A) Income Statement Analysis – Financial Results
- Global Developments, Inc. (GDVM) Income Statement Analysis – Financial Results
- NIKE, Inc. (NKE.BA) Income Statement Analysis – Financial Results
Adial Pharmaceuticals, Inc. (ADIL)
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 564.00 | 60.50K | 55.11K | 564.00 | 565.00 | 563.00 | 565.00 | 565.00 | 565.00 |
| Gross Profit | -564.00 | -60.50K | -55.11K | -564.00 | -565.00 | -563.00 | -565.00 | -565.00 | -565.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.27M | 4.18M | 8.40M | 5.85M | 3.97M | 368.46K | 182.11K | 146.14K | 322.11K |
| General & Administrative | 5.62M | 9.14M | 9.34M | 5.07M | 4.28M | 6.62M | 813.18K | 264.66K | 497.15K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.62M | 9.14M | 9.34M | 5.07M | 4.28M | 6.62M | 813.18K | 264.66K | 497.15K |
| Other Expenses | 0.00 | 0.00 | 46.49K | 2.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.89M | 13.32M | 17.74M | 10.93M | 8.24M | 6.99M | 995.29K | 410.81K | 819.26K |
| Cost & Expenses | 6.89M | 13.32M | 17.74M | 10.93M | 8.24M | 6.99M | 995.29K | 410.81K | 819.26K |
| Interest Income | 69.78K | 63.34K | 6.54K | 32.50K | 95.23K | 7.39K | 367.00 | 240.00 | 1.26K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.17M | 144.54K | 9.64K | 0.00 | |
| Depreciation & Amortization | 564.00 | 564.00 | 55.11K | 564.00 | 565.00 | 563.00 | 565.00 | 565.00 | 565.00 |
| EBITDA | -7.00M | -13.32M | -19.46M | -10.93M | -8.15M | -6.98M | -994.35K | -410.00K | -817.43K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.89M | -13.32M | -19.29M | -10.93M | -8.24M | -6.99M | -995.29K | -410.81K | -819.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -113.94K | 585.21K | -1.82M | 35.00K | -346.53K | -4.64M | -144.17K | -9.39K | 1.26K |
| Income Before Tax | -7.00M | -12.73M | -19.52M | -10.89M | -8.59M | -11.63M | -1.14M | -420.20K | -817.99K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -502.00 | -94.08K | -32.50K | -76.06K | -3.48M | 367.00 | 9.64K | 1.26K |
| Net Income | -7.00M | -12.73M | -19.42M | -10.86M | -8.59M | -11.63M | -1.14M | -420.20K | -817.99K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.44 | -11.98 | -26.12 | -21.79 | -21.80 | -61.10 | -5.20 | -2.20 | -4.28 |
| EPS Diluted | -5.44 | -11.98 | -26.12 | -21.79 | -21.80 | -61.10 | -5.20 | -2.20 | -4.28 |
| Weighted Avg Shares Out | 1.42M | 1.06M | 743.55K | 498.53K | 394.10K | 190.37K | 218.99K | 191.13K | 191.28K |
| Weighted Avg Shares Out (Dil) | 1.42M | 1.06M | 743.55K | 498.53K | 394.10K | 190.37K | 218.99K | 191.13K | 191.28K |
Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom Fisher
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the...
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).
Adial Clinical Trial: A Fluff Or A Win?
Onward Phase III Clinical Trial of Adial Pharmaceutical's AD04, a treatment for Alcohol Abuse Disorder, was completed in early 2022. A subset of study participants, the Heavy Drinker group, demonstrated clear benefit from AD04 with a 79% reduction in heavy...
What's Going On With Adial Pharmaceuticals Stock Today?
Shares of small-cap penny stock Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) shares are trading about 20.5% lower at $1.46 per share Wednesday morning. The company announced topline results for its Onward Phase 3 trial for AD04 in patients with Alcohol Use Disorder.
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Adial Pharmaceuticals, Inc. (ADIL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates...
5 Winning Stocks Backed by the Overlooked Rising P/E Strategy
Want to try an out-of-the-box approach? Tap five stocks (GIII, PPC, TAL, ADIL and CHS) with increasing P/E ratios.
Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.
Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 Conference
CHARLOTTESVILLE, Va., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William...
Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate
Adial Pharmaceuticals Inc (NASDAQ: ADIL) has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound for its program to develop pain management drugs.
Source: https://incomestatements.info
Category: Stock Reports